Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FDJQ0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,618
Award facts
- Contract value 100% obligated
- $16,617.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a delivery order valued at $16,617.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Botox 200 Unit Vials. The award, issued on January 28, 2026, with an ultimate completion date of February 19, 2026, carries firm fixed-price terms and no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy, enabling the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it to fulfill the diverse and specialized pharmaceutical requirements of Department of Defense healthcare operations. As a registered small business since 2001 with demonstrated substantial federal contracting activity, DMS Pharmaceutical Group has established consistent performance across multiple therapeutic categories and product lines supporting the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FDJQ0?
SPE2DR26FDJQ0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FDJQ0 worth?
The government has obligated $16,618 on SPE2DR26FDJQ0.
Is contract SPE2DR26FDJQ0 an order under another contract?
Yes. SPE2DR26FDJQ0 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJQ0 competed?
The extent of competition for SPE2DR26FDJQ0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award